FindTrial
Sign In

To explore the application of SMI, HALP and molecular detection in predicting the recurrence risk of gastrointestinal stromal tumor in the real world

To explore the application of SMI, HALP and molecular detection in predicting the recurrence risk of gastrointestinal stromal tumor in the real world

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114354
Enrollment
Unknown
Registered
2025-12-10
Start date
2025-12-15
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The stromal tumor recurred after operation

Interventions

Observation group:None

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Preoperative diagnosis of gastrointestinal stromal tumor confirmed by postoperative pathology; 2. Primary, localized gastrointestinal stromal tumor with no other concurrent tumors; 3. Underwent R0 surgical resection; 4. Complete clinical medical records, examination results, and follow-up data.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. Patients who have received other anti-tumor treatments before surgery; 3. Patients with distant metastasis or adjacent organ invasion who only undergo palliative surgery; 4. Cases with significant missing clinical records, examination results, or follow-up data.

Design outcomes

Primary

MeasureTime frame
The stromal tumor recurred after operation;—

Countries

China

Contacts

Public ContactLei Shi

Northern Jiangsu People's Hospital

18051061896@163.com+86 18051061896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026